Senzime AB (publ) Senzime AB (publ)

Senzime AB (publ)

SEZI

Peringkat dalam Saham #25142
Senzime AB (publ) is a medical technology firm specializing in the creation and... Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Harga Saham
$0.31776811
Kapitalisasi Pasar
$49.96M
Perubahan (1 hari)
5.18%
Perubahan (1 tahun)
-54.60%
Negara
SE
Perdagangan Senzime AB (publ) (SEZI)

Kategori

Healthcare
Margin Operasi untuk Senzime AB (publ) (SEZI)
Margin Operasi per 2026 TTM: 0.00%
Menurut laporan keuangan dan harga saham terbaru dari Senzime AB (publ), margin operasi saat ini (TTM) adalah 0.00%. Pada akhir 2026, margin operasi perusahaan adalah 0.00%.
Riwayat margin operasi untuk Senzime AB (publ) dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Margin Operasi untuk perusahaan sejenis atau pesaing
Perusahaan Margin Operasi Perbedaan Margin Operasi Negara
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
17.03% -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
17.86% -
IE
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
22.03% -
US
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
21.46% -
US
Siemens Healthineers AG Siemens Healthineers AG
Siemens Healthineers AG
SHL.DE
0.00% -
DE
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.